Skip to content
★ Sign in to follow
QB

QSAM Biosciences, Inc. Stock: price and insider trades · United States

No insider purchase over the last 90 days. The latest, by Nelson Christopher M., was filed 17 May 2017.

QSAM Biosciences, Inc.: what insiders have been doing

Every trade that managers of QSAM Biosciences, Inc. disclose to SEC (Form 4) is tracked on this page. QSAM Biosciences, Inc. has had no insider filing for more than a year; the last one goes back to 2 May 2024.

The full history, which starts in 2014, counts 4 purchases against no sales.

Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Insider Decl.
25
Thresholds
n/a
Buy Volume
€392,018
4 ops. · all time
Sell Volume
n/a
n/a

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Financial data

as of FY 2017

FY ended December 2017 · cache

Income statement
Revenue66.6k
Gross profit29.7k45% margin
Net income-3.9M-5876.4% margin
Last declaration on 2 May 2024
Declarations25 total
  • ●
    DirectorExecutives
    0SEC
    5 sharesCommon StockSEC:0001493152-24-017512:0
  • ●
    Executive ChairmanExecutives
    0SEC
    188 sharesCommon StockSEC:0001493152-24-017511:0
  • ●
    General Counsel & Executive VPExecutives
    0SEC
    91 sharesCommon StockSEC:0001493152-24-017510:0
  • ●
    DirectorExecutives
    0SEC
    41 sharesCommon StockSEC:0001493152-24-017509:0
  • ●
    Chief Financial OfficerExecutives
    0SEC
    11 sharesCommon StockSEC:0001493152-24-017508:0
  • ●
    CEO/DirectorExecutives
    0SEC
    188 sharesCommon StockSEC:0001493152-24-017507:0
  • ●
    CEO/DirectorExecutives
    3,906 USD30SEC
    1,302 shares@ US$3.00100.0% of flowCommon StockSEC:0001493152-24-006070:0
  • ●
    EVP Corp Dev & General CounselExecutives
    26,049 USD19SEC
    8,683 shares@ US$3.00100.0% of flowCommon StockSEC:0001493152-24-006069:0
  • ◆
    Chief Financial OfficerExecutives
    0SEC
    2,040 sharesCommon StockSEC:0001493152-23-022833:1
  • ◆
    Chief Financial OfficerExecutives
    0SEC
    20,910 shares0Common StockSEC:0001493152-23-022833:0
  • ◆
    EVP Corp Dev & General CounselExecutives
    0SEC
    46,365 shares0Common StockSEC:0001493152-23-022262:0
  • ◆
    CEO/DirectorExecutives
    0SEC
    72,276 shares0Common StockSEC:0001493152-23-022264:0
  • ◆
    DirectorExecutives
    0SEC
    10,455 shares0Common StockSEC:0001493152-23-022266:0
  • ◆
    DirectorExecutives
    0SEC
    10,455 shares0Common StockSEC:0001493152-23-022267:0
  • ◆
    Executive ChairmanExecutives
    0SEC
    72,276 shares0Common StockSEC:0001493152-23-022265:0
  • ◆
    CEO / DirectorExecutives
    0SEC
    50,926 sharesCommon StockSEC:0001493152-23-000364:0
  • ◆
    General CounselExecutives
    0SEC
    37,037 sharesCommon StockSEC:0001493152-23-000362:0
  • ◆
    Executive ChairmanExecutives
    0SEC
    53,241 sharesCommon StockSEC:0001493152-23-000360:0
  • ▲
    CEOExecutives
    100,000 USD38SEC
    5,000,000 shares@ US$0.0244.6% of flowCommon StockSEC:0001529012-17-000001:0
    Canonical exit: 28 May 2017 (T+90)
  • ▲
    CEOExecutives
    100,000 USD28SEC
    666,667 shares@ US$0.1544.0% of flowcommon stockSEC:0001529012-17-000001:1
    Canonical exit: 29 Jun 2017 (T+90)
  • ▲
    DirectorExecutives
    200,000 USD33SEC
    10,000,000 shares@ US$0.0293.0% of flowcommon stockSEC:0001673956-17-000001:0
    Canonical exit: 28 May 2017 (T+90)
  • ▲
    DirectorExecutives
    16,000 USD12SEC
    100,000 shares@ US$0.167.0% of flowcommon stockSEC:0001673956-16-000002:0
    Canonical exit: 15 Nov 2016 (T+90)
  • ●
    Executives
    0SEC
    2,373,931 shares0Common StockSEC:0001548123-15-000419:0
  • ◆
    CFO, SecretaryExecutives
    1,020 USD0SEC
    17,000 shares@ US$0.06Common StockSEC:0001010412-15-000091:0
  • ◆
    DirectorExecutives
    30,000 USD0SEC
    400,000 shares@ US$0.075Common StockSEC:0001010412-14-000135:0

25 of 25 declarations

About QSAM Biosciences, Inc.

QSAM Biosciences, Inc. is a biotechnology company focused on developing innovative treatments for cancer. It specializes in the research and commercialization of targeted therapeutic solutions.